BiotechTube

TNX-102 SL Tablet, 2.8mg + Placebo SL Tablet

Phase 3Completed
0 watching 0 views this week📈 Rising
69
Hype Score

Development Stage

✓
Pre-clinical
✓
Phase 1
✓
Phase 2
4
Phase 3
5
Approved
Indication / Disease

Fibromyalgia

Conditions

Fibromyalgia, Myofascial Pain Syndromes, Muscular Diseases, Musculoskeletal Diseases, Nervous System Diseases, Neuromuscular Diseases, Rheumatic Diseases

Trial Timeline

Apr 1, 2015 → Sep 1, 2016

NCT ID
NCT02436096

About TNX-102 SL Tablet, 2.8mg + Placebo SL Tablet

TNX-102 SL Tablet, 2.8mg + Placebo SL Tablet is a phase 3 stage product being developed by Tonix Pharmaceuticals for Fibromyalgia. The current trial status is completed. This product is registered under clinical trial identifier NCT02436096. Target conditions include Fibromyalgia, Myofascial Pain Syndromes, Muscular Diseases.

Hype Score Breakdown

Clinical
27
Activity
18
Company
2
Novelty
9
Community
10

Clinical Trials (1)

NCT IDPhaseStatus
NCT02436096Phase 3Completed

Competing Products

20 competing products in Fibromyalgia

See all competitors
ProductCompanyStageHype Score
DS-5565 + Pregabalin + Placebo tablet + Placebo capsuleDaiichi SankyoPhase 3
77
DS-5565Daiichi SankyoPhase 3
77
DS-5565 + PlaceboDaiichi SankyoPhase 3
77
DS-5565 + Pregabalin + Placebo tablet + Placebo capsuleDaiichi SankyoPhase 3
77
DS-5565 + Pregabalin + Placebo tablet + Placebo capsuleDaiichi SankyoPhase 3
77
ASP8062 + PlaceboAstellas PharmaPhase 2
52
ASP0819 + PlaceboAstellas PharmaPhase 2
52
DuloxetineShionogiPhase 3
77
Duloxetine 60 mg + PlaceboShionogiPhase 3
77
zonisamideEisaiApproved
85
ONO-1110 + PlaceboOno PharmaceuticalPhase 2
52
DuloxetineEli LillyApproved
85
duloxetine hydrochloride + placeboEli LillyApproved
85
duloxetineEli LillyPhase 3
77
Duloxetine + placeboEli LillyPhase 3
77
Duloxetine + PlaceboEli LillyPhase 3
77
Duloxetine + PlaceboEli LillyApproved
85
Treatment for FibromyalgiaEli LillyPre-clinical
23
Duloxetine + PlaceboEli LillyPhase 3
77
duloxetine + placeboEli LillyPhase 3
77

Other Products from Tonix Pharmaceuticals

TNX-102 SLPhase 3
69
TNX-102 SL 5.6 mgPhase 3
69
TNX-102 SL Tablet, 2.8 mg + Placebo SL TabletPhase 3
69
TNX-102 SL + Placebo SL TabletPhase 3
69
TNX-102 SL Tablet 2.8 mgPhase 3
69